The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Open accessPublished version of a preprint
Abstract
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 therapies is unclear. We created a novel genetically engineered mouse model of HCC that enables interrogation of how different genetic alterations affect immune surveillance and response to immunotherapies. Expression of exogenous antigens in MYC;Trp53−/− HCCs led to T cell–mediated immune surveillance, which was accompanied by decreased tumor formation and increased survival. Some antigen-expressing MYC;Trp53−/− HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway. Accordingly, expression of exogenous antigens in MYC;CTNNB1 HCCs had no effect, demonstrating that β-catenin promoted immune escape, which involved defective recruitment of dendritic cells and consequently impaired T-cell activity. Expression of chemokine CCL5 in antigen-expressing MYC;CTNNB1 HCCs restored immune surveillance. Finally, β-catenin–driven tumors were resistant to anti–PD-1. In summary, β-catenin activation promotes immune escape and resistance to anti–PD-1 and could represent a novel biomarker for HCC patient exclusion. Significance: Determinants of response to anti–PD-1 immunotherapies in HCC are poorly understood. Using a novel mouse model of HCC, we show that β-catenin activation promotes immune evasion and resistance to anti–PD-1 therapy and could potentially represent a novel biomarker for HCC patient exclusion. See related commentary by Berraondo et al., p. 1003. This article is highlighted in the In This Issue feature, p. 983
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a mouse model of HCC, activation of WNT–β-catenin signalling promotes immune escape by impairing recruitment of dendritic cells and interfering with recognition by natural killer cells73.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 928
Luo, J., Gong, L., Yang, Y., Zhang, Y., Liu, Q., Bai, L., Fang, X., Zhang, B., Huang, J., Liu, M., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000299 · Cited by 43
Lu, X., Deng, S., Xu, J., Green, B. L., Zhang, H., Cui, G., Zhou, Y., Zhang, Y., Xu, H., Zhang, F., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163291 · Cited by 44
Human-correlated genetic models identify precision therapy for liver cancer
Müller, M., May, S., Hall, H., Kendall, T. J., McGarry, L., Blukacz, L., Nuciforo, S., Γεωργακοπούλου, Α., Jamieson, T., Phinichkusolchit, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08585-z · Cited by 40
Self-citationPrecision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
Lehrich, B. M., Delgado, E. R., Yasaka, T. M., Liu, S., Cao, C., Liu, Y., Taheri, M. N., Guan, X., Koeppen, H., Singh, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60457-2 · Cited by 45
Self-citationCao, P., Ma, B., Sun, D., Zhang, W., Qiu, J., Qin, L., & Xue, X. (2021) · Cancer Science · doi:10.1111/cas.15238 · Cited by 40
Jiang, T., Rivera, F. J. S., Soto‐Feliciano, Y. M., Yang, Q., Song, C., Bhuatkar, A., Haynes, C. M., Hemann, M. T., & Xue, W. (2020) · Hepatology · doi:10.1002/hep.31685 · Cited by 40
Yang, Y., Wu, J., Liu, F., He, J. H., Wu, F., Chen, J., & Jiang, Z. (2021) · Stem Cells and Development · doi:10.1089/scd.2021.0153 · Cited by 41
Yamauchi, M., Ono, A., Amioka, K., Fujii, Y., Nakahara, H., Teraoka, Y., Uchikawa, S., Fujino, H., Nakahara, T., Murakami, E., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00390-x · Cited by 40
Specific features of ß-catenin-mutated hepatocellular carcinomas
Dantzer, C., Dif, L., Vaché, J., Basbous, S., Billottet, C., & Moreau, V. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02849-7 · Cited by 42
Liu, F., Li, X., Zhang, Y., Ge, S., Shi, Z., Liu, Q., & Jiang, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03490-9 · Cited by 45
The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
Aghbash, P. S., Hemmat, N., Baradaran, B., Mokhtarzadeh, A., Poortahmasebi, V., Oskouee, M. A., & Baghi, H. B. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.026776 · Cited by 39
Li, Z., de Fromentel, C. C., Kim, W., Wang, W., Sun, J., Yan, B., Utturkar, S. M., Lanman, N. A., Elzey, B. D., Yeo, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06302-0 · Cited by 38
Advances in Immunotherapy in Hepatocellular Carcinoma
Bloom, M., Podder, S., Dang, H. T., & Lin, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051936 · Cited by 38
Diverse immune response of DNA damage repair-deficient tumors
Qing, T., Jun, T. W., Lindblad, K. E., Lujambio, A., Marczyk, M., Pusztai, L., & Huang, K. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100276 · Cited by 37
Self-citationTeijeira, Á., Garasa, S., Luri‐Rey, C., de Andrea, C., Gato, M., Molina, C., Kaisho, T., Cirella, A., Azpilikueta, A., Wculek, S. K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1046 · Cited by 39
Zhao, H., Ling, Y., He, J., Dong, J., Mo, Q., Wang, Y., Zhang, Y., Hongbin, Y., & Tang, C. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101084 · Cited by 38
CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer
Liu, Y., Wang, F., Yan, G., Tong, Y., Guo, W., Li, S., Qian, Y., Li, Q., Shu, Y., Zhang, L., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217006 · Cited by 39
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges
Rizzo, A., Brunetti, O., & Brandi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011091 · Cited by 41
Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy
Huang, S.-L., Wang, Y., Wang, Q.-Y., Feng, G.-G., Wu, F., Yang, L., Zhang, X.-H., & Xin, H.-W. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.691391 · Cited by 37
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma
Muhammed, A., D’Alessio, A., Enica, A., TALBOT, T. L., Fulgenzi, C. A. M., Nteliopoulos, G., Goldin, R. D., Cortellini, A., & Pinato, D. J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2049244 · Cited by 35
131I-αPD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer
Qi, Z., Pei, P., Zhang, Y., Chen, H., Yang, S., Liu, T., Zhang, Y., & Yang, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.029 · Cited by 38
Fang, X., Yan, Q., Liu, S., & Guan, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012327 · Cited by 37
Barat, M., Pellat, A., Hoeffel, C. C., Dohan, A. J. J., Coriat, R., Fishman, E. K., Nougaret, S., Chu, L. C. H., & Soyer, P. A. (2023) · Japanese Journal of Radiology · doi:10.1007/s11604-023-01504-0 · Cited by 35
Nishida, N., & Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051274 · Cited by 36
β-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy
Krutsenko, Y., Singhi, A. D., & Monga, S. P. (2021) · Cancers · doi:10.3390/cancers13081830 · Cited by 36
Self-citationLiquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
Maravelia, P., Silva, D. N., Rovesti, G., Chrobok, M., Stal, P. I., Lu, Y., & Pasetto, A. (2021) · Cancers · doi:10.3390/cancers13174334 · Cited by 38
Tao, L., Wang, S., Kang, G., Jiang, S., Yin, W., Zong, L., Li, J., & Wang, X. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2002068 · Cited by 36
Self-citationMorita, M., Nishida, N., Aoki, T., Chishina, H., Takita, M., Ida, H., Hagiwara, S., Minami, Y., Ueshima, K., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15082311 · Cited by 40
Singh, D., & Siddique, H. R. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10141-y · Cited by 38
Duan, J., Zhang, Y., Chen, R., Liang, L., Huo, Y., Lü, S., Zhao, J., Hu, C., Sun, Y., Yang, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101302 · Cited by 35
Clinical Significance of the Duality of Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma
Aoki, T., Nishida, N., & Kudo, M. (2022) · Cancers · doi:10.3390/cancers14020444 · Cited by 35
Ji, J. H., Ha, S. Y., Lee, D., Sankar, K. N., Koltsova, E. K., Abou‐Alfa, G. K., & Yang, J. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087640 · Cited by 34
Weng, J., Wang, Z., Hu, Z., Xu, W., Sun, J.-L., Wang, F., Zhou, Q., Liu, S., Xu, M., Xu, M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3106 · Cited by 35
Wnt/β-Catenin Signaling in Liver Pathobiology
Carson, M. D., & Nejak‐Bowen, K. N. (2024) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023535 · Cited by 36
Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation
Berraondo, P., Ochoa, M. C., Olivera, I., & Melero, I. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0696 · Cited by 34
Kurebayashi, Y., Kubota, N., & Sakamoto, M. (2020) · Hepatology Research · doi:10.1111/hepr.13539 · Cited by 35
Molina, L. M., Zhu, J., Trépo, E., Bayard, Q., Amaddeo, G., Bail, B. L., Chiche, L., Bioulac‐Sage, P., Balabaud, C. P., Possenti, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.018 · Cited by 36
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies
Lerário, A. M., Mohan, D. R., & Hammer, G. D. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac012 · Cited by 36
Huang, Y., Peng, M., Yu, W., & Li, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112534 · Cited by 33
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
He, Y., Lu, M., Che, J., Chu, Q., Zhang, P., & Chen, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716844 · Cited by 34
Liu, L., Liu, Z., Gao, J., Liu, X., Weng, S., Guo, C., Hu, B., Wang, Z., Zhang, J., Shi, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964190 · Cited by 33
Generation of precision preclinical cancer models using regulated in vivo base editing
Katti, A., Vega‐Pérez, A., Foronda, M., Zimmerman, J., Zafra, M. P., Granowsky, E., Goswami, S., Gardner, E. E., Diaz, B. J., Simon, J. M., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01900-x · Cited by 34
Samant, C., Kale, R. R., Pai, K. S. R., Nandakumar, K., & Bhonde, M. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150348 · Cited by 35
Huang, H.-Y., Chen, Y.-Z., Zhao, C., Zheng, X.-N., Yu, K., Yue, J., Ju, H., Shi, Y., & Tian, L. H. (2024) · Nature Communications · doi:10.1038/s41467-024-53659-7 · Cited by 39
Akasu, M., Shimada, S., Kabashima, A., Akiyama, Y., Shimokawa, M., Akahoshi, K., Kudo, A., Yamaoka, S., Tanabe, M., & Tanaka, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-96167-0 · Cited by 32
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Zhong, C. F., Li, Y., Yang, J., Jin, S., Chen, G., Li, D., Fan, X., & Lin, H. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.589680 · Cited by 32
Cellular based immunotherapy for primary liver cancer
Zheng, Y., Li, Y., Feng, J., Li, J., Ji, J., Wu, L., Yu, Q., Dai, W., Wu, J., Zhou, Y., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02030-5 · Cited by 32
The Wnt/β-catenin signaling pathway in the tumor microenvironment of hepatocellular carcinoma
Wang, K., Qiu, X., Zhao, Y., Wang, H., & Chen, L. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0306 · Cited by 32
Antimetastatic defense by CD8+ T cells
de Lara, P. T., Castañón, H., Sterpi, M., & van den Broek, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.006 · Cited by 32
Paschen, A., Melero, I., & Ribas, A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070220-111016 · Cited by 32
Xie, Q., Zhang, P., Wang, Y., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958720 · Cited by 35
Budhu, A., Pehrsson, E. C., He, A. R., Goyal, L., Kelley, R. K., Dang, H. T., Xie, C., Monge, C., Tandon, M., Ma, L., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101052 · Cited by 33
Lai, G., Xie, B., Zhang, C., Zhong, X., Deng, J., Li, K., Liu, H., Zhang, Y., Liu, A., Liu, Y., et al. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101471 · Cited by 35
Girardi, D. M., Pacifico, J. P. M., de Amorim, F. P. L. G., Fernandes, G. D. S., Teixeira, M. C., & Pereira, A. A. L. (2020) · Pharmaceuticals · doi:10.3390/ph14010028 · Cited by 30
Huang, S., Li, T., Chen, Y., Liu, J., Wang, Y., Yang, C., Wang, C., Ju, S., Bai, Y., Yao, W., et al. (2022) · International Journal of Hyperthermia · doi:10.1080/02656736.2022.2032406 · Cited by 31
He, F., Wu, Z., Liu, C., Zhu, Y., Zhou, Y., Tian, E., Rosin‐Arbesfeld, R., Yang, D., Wang, M., & Zhu, D. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01838-9 · Cited by 31
Rialdi, A., Duffy, M. E., Scopton, A. P., Fonseca, F., Zhao, J. N., Schwarz, M. C., Molina-Sánchez, P., Mzoughi, S., Arceci, E., Abril‐Fornaguera, J., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00609-9 · Cited by 30
Self-citationYu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 31
Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges
Cigliano, A., Liao, W., Deiana, G. A., Rizzo, D., Chen, X., & Calvisi, D. F. (2024) · Biomedicines · doi:10.3390/biomedicines12071624 · Cited by 32
Chung, A. S., Mettlen, M., Ganguly, D., Lu, T., Wang, T., Brekken, R. A., Hsiehchen, D., & Zhu, H. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0200 · Cited by 29
Chen, D., Bao, X., Zhang, R., Ding, Y., Zhang, M., Li, B., Zhang, H., Li, X., Tong, Z., Liu, L., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01501-y · Cited by 30
Self-citationGenetic tools for the stable overexpression of circular RNAs
Mecozzi, N., Nenci, A., Vera, O., Bok, I., Falzone, A., DeNicola, G. M., & Karreth, F. A. (2022) · RNA Biology · doi:10.1080/15476286.2022.2043041 · Cited by 29
Shi, Y., Lin, G., Zheng, H., Mu, D., Chen, H., Lu, Z., He, P., Zhang, Y., Liu, C., Lin, Z., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01189-5 · Cited by 31
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10406-8 · Cited by 29
Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer
Graham, M. K., Wang, R., Chikarmane, R. V., Abel, B., Vaghasia, A. M., Gupta, A., Zheng, Q., Hicks, J. L., Sysa‐Shah, P., Pan, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51450-2 · Cited by 28
Changes in therapeutic options for hepatocellular carcinoma in Asia
Ogasawara, S., Koroki, K., Kanzaki, H., Kobayashi, K., Kiyono, S., Nakamura, M., Kanogawa, N., Saito, T., Kondo, T., Nakagawa, R., et al. (2021) · Liver International · doi:10.1111/liv.15101 · Cited by 28
The Portrait of Liver Cancer is Shaped by Mitochondrial Genetics
Chattopadhyay, M., Jenkins, E. C., Lechuga‐Vieco, A. V., Nie, K., Fiel, M. I., Rialdi, A., Guccione, E., Enrı́quez, J. A., Sia, D., Lujambio, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110254 · Cited by 28
Self-citationShah, A. H., Govindarajan, V., Doucet-O’Hare, T. T., Rivas, S. R., Ampie, L., DeMarino, C., Banasavadi‐Siddegowda, Y., Zhang, Y., Johnson, K. R., Almsned, F. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10914-5 · Cited by 28
The mechanisms on evasion of anti-tumor immune responses in gastric cancer
Wang, J., Liu, T., Huang, T., Shang, M., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943806 · Cited by 28
Yu, Z., Feng, H., Zhuo, Y., Li, M., Zhu, X., Huang, L., Zhang, X., Zhou, Z., Zheng, C., Jiang, Y., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00546-0 · Cited by 27
Pelizzaro, F., Farinati, F., & Trevisani, F. (2023) · Biomedicines · doi:10.3390/biomedicines11041020 · Cited by 28
Unravelling immune microenvironment features underlying tumor progression in the single-cell era
Du, Q., An, Q., Zhang, J., Liu, C., & Hu, Q. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03335-z · Cited by 27
Zeng, Y., Huang, Y., Tan, Q., Peng, L., Wang, J., Tong, F., & Dong, X. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13413 · Cited by 31
Guo, X., Cui, T., Sun, L., Fu, Y., Cheng, C., Wu, C., Zhu, Y., Liang, S., Liu, Y., Zhou, S., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01432-0 · Cited by 28
Ge, Y., Zhou, Q., Pan, F., & Wang, R. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s505539 · Cited by 28
Silva, L., Egea, J., Villanueva, L., Ruiz, M., Llópiz, D., Repáraz, D., Aparicio, B., Lasarte-Cía, A., Lasarte, J. J., de Galarreta, M. R., et al. (2020) · Cancers · doi:10.3390/cancers12113397 · Cited by 28
Self-citationWang, Z., Zhang, M., Luo, W., Zhang, Y., & Ji, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00046 · Cited by 27
PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
D’Alessio, A., Rimassa, L., Cortellini, A., & Pinato, D. J. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s284440 · Cited by 29
Liu, N., Steer, C. J., & Song, G. (2021) · Hepatology · doi:10.1002/hep.32182 · Cited by 27
Chen, H., Chen, J., Yuan, H., Li, X., & Li, W. (2022) · Oncology Letters · doi:10.3892/ol.2022.13404 · Cited by 29
Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma
Shen, W., Chen, Y., Pan, L., Sheldon, M., Sun, Y., Yao, F., & Ma, L. (2022) · Cancers · doi:10.3390/cancers14205013 · Cited by 27
Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 30
Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
Melero, I., Ochoa, M. C., Molina, C., Sánchez‐Gregorio, S., Garasa, S., Luri‐Rey, C., Hervás‐Stubbs, S., Casares, N., Elizalde, E., Gomis, G., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317804 · Cited by 26
Wang, K., Wu, J., Zhao, Y., Zheng, B. J., Shen, S., Wang, R., Zhang, Y., Wang, H., Chen, L., & Qiu, X. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216690 · Cited by 26
Embracing diversity: macrophage complexity in cancer
Hochstadt, J., Pacheco, S. M., & Casanova-Acebes, M. (2025) · Trends in cancer · doi:10.1016/j.trecan.2024.12.002 · Cited by 28
Self-citationMonti, E., Vianello, C., Leoni, I., Galvani, G., Lippolis, A., D’Amico, F., Roggiani, S., Stefanelli, C., Turroni, S., & Fornari, F. (2025) · Cells · doi:10.3390/cells14020084 · Cited by 28
Zheng, H., Chen, Y., Luo, W., Han, S., Sun, M., Min, L., Wu, C.-H., Gao, L., Xie, T., & Kong, N. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03378-y · Cited by 27
ICOS limits memory-like properties and function of exhausted PD-1 + CD8 T cells
Humblin, É., Korpas, I., Prokhnevska, N., Vaidya, A. B., Filipescu, D., Lu, J., van der Heide, V., Fraga, C. A. D. C., Bobrowski, T., Marks, A. R., et al. (2024) · Immunity · doi:10.1016/j.immuni.2025.06.001 · Cited by 26
Self-citationFrontline therapy for advanced hepatocellular carcinoma: an update
Akce, M., El‐Rayes, B. F., & Bekaii‐Saab, T. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221086126 · Cited by 26
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Zhu, Y., & Qin, L. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.003 · Cited by 26
Hosoda, S., Suda, G., Sho, T., Ogawa, K., Kimura, M., Yang, Z., Yoshida, S., Kubo, A., Tokuchi, Y., Kitagataya, T., et al. (2022) · Liver Cancer · doi:10.1159/000527759 · Cited by 26
Luo, H., Hu, B., Gu, X.-R., Chen, J., Fan, X., Zhang, W., Wang, R., He, X.-D., Guo, W., Dai, N., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02201-w · Cited by 25
Liu, S., Zhou, Y., Li, G., Zhu, B., Wu, F., Zhou, J., Chen, X., Qin, B., Gao, Y., Wang, F., et al. (2025) · Advanced Science · doi:10.1002/advs.202507167 · Cited by 25
Borhani, A. A., Catania, R., Velichko, Y., Hectors, S. J. C. G., Taouli, B. A., & Lewis, S. C. (2021) · Abdominal Radiology · doi:10.1007/s00261-021-03085-w · Cited by 25
Prospects and Challenges for T Cell-Based Therapies of HCC
Woller, N., Engelskircher, S. A., Wirth, T. C., & Wedemeyer, H. H. (2021) · Cells · doi:10.3390/cells10071651 · Cited by 25
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
Zhou, G., Boor, P. P. C., Bruno, M. J., Sprengers, D., & Kwekkeboom, J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01453-3 · Cited by 25
Torbenson, M. S., McCabe, C. E., O’Brien, D. R., Yin, J., Bainter, T. M., Tran, N. H., Yasir, S., Chen, Z. E., Dhanasekaran, R., Ahn, K. S., et al. (2021) · Human Pathology · doi:10.1016/j.humpath.2021.09.009 · Cited by 26
Liu, S., Zhang, Y., Qiu, L., Zhang, S., Meng, Y., Huang, C., Chen, Z., Zhang, B., & Han, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.861000 · Cited by 26
Zhou, Y., Chen, L., Ding, D., Li, Z., Cheng, L., You, Q., & Zhang, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-11757-w · Cited by 25
Long, M., Zhou, Z., Wei, X., Lin, Q., Qiu, M., Zhou, Y., Chen, P., Jiang, Y., Wen, Q., Liu, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023349 · Cited by 25
Metadata
- Authors
- Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., Villacorta-Martin, C., Singhi, A. D., Moghe, A., von Felden, J., Tal Grinspan, L., Wang, S., Kamphorst, A. O., Monga, S. P., Brown, B. D., Villanueva, A., Llovet, J. M., Merad, M., & Lujambio, A.
- Affiliations
- 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
- Tisch Cancer Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- 2Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- University of Pittsburgh (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Lujambio, Amaia
- ORCID
- Ruiz de Galarreta, Marina
- Molina-Sánchez, Pedro
- Lindblad, Katherine E.
- Maier, Barbara
- Sia, Daniela
- Puigvehi, Marc
- Miguela, Verónica
- Casanova-Acebes, María
- Dhainaut, Maxime
- Singhi, Aatur D.
- Moghe, Akshata
- von Felden, Johann
- Wang, Shuang
- Kamphorst, Alice O.
- Monga, Satdarshan P.
- Brown, Brian D.
- Villanueva, Augusto
- Llovet, Josep M.
- Lujambio, Amaia
- Venue
- Cancer Discovery
- Published
- 2019-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 1124-1141
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6677618
- OpenAlex
- W2952311394
- Cited by
- 912
- References
- 67
- Citations by year
- 2026: 114 · 2025: 121 · 2024: 158 · 2023: 169 · 2022: 156 · 2021: 116 · 2020: 67 · 2019: 11
- FWCI
- 36.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (DR52-18)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R37CA230636, P30 CA196521)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- β-catenin signaling, hepatocellular carcinoma, immune evasion, anti-PD-1 resistance, PD-1 inhibitors, tumor surveillance, c-Myc, Trp53, dendritic cell recruitment, T cell function, RANTES, chemokines, genetically engineered mouse models, immunotherapy biomarkers
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Dendritic Cells, Disease Models, Animal, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Oncogenes, Biomarkers, Tumor, Signal Transduction, Gene Expression, Treatment Outcome, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Tumor Escape, Xenograft Model Antitumor Assays, Cell Line, Tumor, beta Catenin, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
